Presenters:

Maryland Franklin, PhD | Vice President, Scientific Development
Sarah Krueger, PhD | Scientist, Imaging Operations

Date:

December 2018

Presented December 12, 2018 by MI Bioresearch
Hosted by Xtalks

Overview

More than 50% of all cancer patients receive some sort of radiation therapy as part of their disease treatment plan. However, there remains a persistent lack of drug development with radiation combinations. In order to venture into clinical trials, many drug developers want and need preclinical validation of their strategy. The ability to gain this preclinical proof-of-concept is currently an unmet preclinical need. MI Bioresearch utilizes the Small Animal Radiation Research Platform (SARRP; Xstrahl) to provide image-guided focal beam radiation in preclinical mouse models of oncology. In this webinar, featured speakers will discuss the various models and approaches they have taken to combine focal radiation with immune modulating therapeutics. Both orthotopic and subcutaneous models have been evaluated to determine the ability of radiation to provide synergistic therapeutic benefit. In some models, they have looked at the immune cell modulation following radiation treatment and a discussion on this topic will also be included.

What You Will Learn:

  • Basic radiobiology and role of radiation therapy in oncology treatment
  • Comparison of broad field and focal radiation in preclinical cancer models
  • Sensitivity of murine syngeneic models to focal radiation
  • Ability to combine radiation with checkpoint inhibitors in syngeneic models
  • Ability to combine radiation with costimulatory agonists in syngeneic models
  • Focal radiation and modulation of immune cell populations in syngeneic models

 

Due to the amount of data presented, please contact us by filling out the form on this page to request a copy of the webinar video (MP4).